Merck, with a heavy presence in physician-administered drugs, predicts a $2.1B sales hit from COVID-19

28th April 2020 Uncategorised 0

While drugmakers across the industry deal with their respective COVID-19 challenges, Merck faces a unique set of circumstances because of its reliance on physician-administered drugs. Several companies have reaffirmed their 2020 revenue expectations, but Merck’s management just laid out expectations for a multibillion-dollar hit to 2020 sales.

More: Merck, with a heavy presence in physician-administered drugs, predicts a .1B sales hit from COVID-19
Source: fierce